新~?GnRH-a~~黃體素的 運用~~ 增成功率（美國）Johns Hopkins

新黃體素 運用 增成功率（美國）10.7聽說胚胎著床那天打一種針，可增加成功率？
Gynecology and Obstetrics, Johns Hopkins Medical Institution, Baltimore, MD; Muasher Center for Fertility and IVF, Fairfax, VA


GnRH-agonist administration in the mid-luteal phase yields favorable pregnancy and implantation rates in stimulated in vitro fertilization cycles with GnRH-antagonist

Z.R. Hubayter, A. Rettberg, A. Ibrahim, H. Zacur, J. Garcia, S.J. Muasher
P-763

Article Outline

• Copyright
OBJECTIVE: Our goal was to assess a novel role for GnRH-agonist as a supplement in luteal phase. GnRH-agonist receptors are present in the endometrium and the ovaries. Furthermore, the corpus luteum function may improve with GnRH-agonist induced endogenous flare with pituitary hormones. In vitro, GnRH-agonists have improved mouse embryo developement. Recent studies have demonstrated improved implantation rate with the use of a single dose GnRH-agonist 6 days after oocyte retreival in an IVF cycle (Tesarik, Hum Reprod, 2006,21: 2572-9). Our objective was to evaluate the impact of a daily GnRH-agonist at the time of implantation (Days 5-7 following retreival) on IVF outcomes in antagonist cycles.


GnRH-agonist administration in the mid-luteal phase yields favorable pregnancy and implantation rates in stimulated in vitro fertilization cycles with GnRH-antagonist

Z.R. Hubayter, A. Rettberg, A. Ibrahim, H. Zacur, J. Garcia, S.J. Muasher
P-763

Article Outline

Category:

People & Blogs

Tags:

• 新黃體素增成功率（美國）